Real world characteristics and outcomes of patients with BRAFV600E-mutant metastatic colorectal cancer in Australia: The COALA project.
Nadia Hitchen(Peter MacCallum Cancer Centre), Jeanne Tie(The Royal Melbourne Hospital), Matthew Burge(Royal Brisbane and Women's Hospital), Hiren Mandaliya(Lake Macquarie Private Hospital), Vanessa Wong(Walter and Eliza Hall Institute of Medical Research), Theresa Hayes(St John of God Hospital), Azim Jalali(Walter and Eliza Hall Institute of Medical Research), Peter Gibbs(The University of Melbourne), Susan Caird(Gold Coast Hospital), Belinda Lee(Walter and Eliza Hall Institute of Medical Research), Stephanie Lim(Camden and Campbelltown Hospitals), Angus Campbell(Walter and Eliza Hall Institute of Medical Research), Natalie Rainey(Queensland Government), Jeremy Shapiro(Cabrini Hospital), Rachel Wong(Box Hill Hospital), Shu Fen Wong(Barwon Health), Javier Torres(Goulburn Valley Health), Louise Nott(Royal Hobart Hospital), Adnan Khattak(Edith Cowan University), Hui‐Li Wong(Walter and Eliza Hall Institute of Medical Research)
Cited by 1
Related Papers
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
|Science Translational Medicine|2014|5.1k
<i>K-ras</i> Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
|New England Journal of Medicine|2008|3.6k
Detection and localization of surgically resectable cancers with a multi-analyte blood test
|Science|2018|2.8k
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
|New England Journal of Medicine|2018|1.9k
Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer
|Science Translational Medicine|2016|1.5k